Vincerx Pharma (VINC) Proxy Filing summary

Executive summary

• Special Meeting of Stockholders scheduled for August 12, 2024, to vote on a Stock Option Repricing and Exchange Program.

• The program aims to reprice eligible stock options and offer an exchange for RSUs, with updated vesting schedules and retention periods.

• Only current employees and consultants (not non-employee directors) with outstanding, non-exercised options are eligible.

• The Compensation Committee will determine the exchange ratio to ensure value neutrality and minimize additional compensation expense.

• Implementation is contingent on shareholder approval, with flexibility for the board to amend or terminate the program.

Voting matters and shareholder proposals

• Shareholders are asked to approve the Stock Option Repricing and Exchange Program at the Special Meeting.

• Approval will allow repricing of options and commencement of the exchange for RSUs.

• Voting instructions remain valid unless changed or revoked by the shareholder.

Board of directors and corporate governance

• The board, based on the Compensation Committee's recommendation, approved the program subject to shareholder approval.

• The Compensation Committee retains authority to determine exchange ratios and program details.

• The board and committee may amend, postpone, or terminate the exchange at their discretion before completion.